- Home
- ZNTL vs ATOS Comparison
ZNTL vs ATOS Comparison
Compare ZNTL & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- ATOS
- Stock Information
- Founded
- ZNTL 2014
- ATOS 2009
- Country
- ZNTL United States
- ATOS United States
- Employees
- ZNTL N/A
- ATOS N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- ZNTL Health Care
- ATOS Health Care
- Exchange
- ZNTL Nasdaq
- ATOS Nasdaq
- Market Cap
- ZNTL 105.8M
- ATOS 107.2M
- IPO Year
- ZNTL 2020
- ATOS 2012
- Fundamental
- Price
- ZNTL $1.33
- ATOS $0.94
- Analyst Decision
- ZNTL Buy
- ATOS Strong Buy
- Analyst Count
- ZNTL 7
- ATOS 3
- Target Price
- ZNTL $8.60
- ATOS $6.17
- AVG Volume (30 Days)
- ZNTL 1.4M
- ATOS 1.5M
- Earning Date
- ZNTL 08-08-2025
- ATOS 08-11-2025
- Dividend Yield
- ZNTL N/A
- ATOS N/A
- EPS Growth
- ZNTL N/A
- ATOS N/A
- EPS
- ZNTL N/A
- ATOS N/A
- Revenue
- ZNTL $26,865,000.00
- ATOS N/A
- Revenue This Year
- ZNTL N/A
- ATOS N/A
- Revenue Next Year
- ZNTL N/A
- ATOS N/A
- P/E Ratio
- ZNTL N/A
- ATOS N/A
- Revenue Growth
- ZNTL N/A
- ATOS N/A
- 52 Week Low
- ZNTL $1.01
- ATOS $0.55
- 52 Week High
- ZNTL $5.44
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- ZNTL 50.91
- ATOS 58.44
- Support Level
- ZNTL $1.15
- ATOS $0.81
- Resistance Level
- ZNTL $1.38
- ATOS $0.88
- Average True Range (ATR)
- ZNTL 0.10
- ATOS 0.05
- MACD
- ZNTL 0.01
- ATOS 0.01
- Stochastic Oscillator
- ZNTL 75.00
- ATOS 84.07
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.